Javelin Pharmaceuticals, Inc. (Amex: JAV) today reported that it has completed its open-label multi-dose, multi-day, observational safety study of Dyloject ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE